Anticancer Activity in Heterocyclic Organic Structures: A Pathway to Novel Drug Development Part 1
暫譯: 雜環有機結構中的抗癌活性：新藥開發之途徑 第1部分
El McHichi, Larbi, Bouachrine, Mohammed, Lakhlifi, Tahar
相關主題
商品描述
This new volume in New Directions in Organic & Biological Chemistry, explores the development of cancer therapeutics, focusing on molecular chemistry and advanced drug design approaches. Written by experts in theoretical chemistry and molecular chemistry, they bridge the gap between theoretical chemistry, molecular biology, and drug development. In Part I, they focus on the fundamental properties of heterocyclic compounds and innovative methodologies being employed to enhance therapeutic potential. By exploring various classes of heterocyclic compounds and diverse anticancer mechanisms, this book provides a valuable resource for researchers, pharmaceutical scientists, and oncologists.
- Provides an overview of computational approaches used in drug discovery, including molecular docking, QSAR, and virtual screening.
- Focuses on the theoretical and practical aspects of these techniques, with applications across various therapeutic areas, including cancer.
- Addresses the challenges in translating scientific research into effective treatments, offering insights into overcoming common obstacles in the development process.
- These compounds represent a significant opportunity for the pharmaceutical industry to provide more effective and tailored cancer treatments, further driving market growth.
- The breadth of the market for heterocyclic anticancer agents is vast and continues to expand as scientific advancements uncover new therapeutic targets.
商品描述(中文翻譯)
這本《有機與生物化學新方向》系列的新書探討了癌症治療藥物的發展，重點在於分子化學和先進的藥物設計方法。這本書由理論化學和分子化學的專家撰寫，彌合了理論化學、分子生物學和藥物開發之間的鴻溝。在第一部分中，他們專注於雜環化合物的基本特性以及用於增強治療潛力的創新方法。通過探索各類雜環化合物和多樣的抗癌機制，本書為研究人員、藥物科學家和腫瘤科醫生提供了寶貴的資源。
- 提供了藥物發現中使用的計算方法概述，包括分子對接（molecular docking）、定量結構-活性關係（QSAR）和虛擬篩選（virtual screening）。
- 專注於這些技術的理論和實踐方面，並在包括癌症在內的各種治療領域中應用。
- 解決了將科學研究轉化為有效治療的挑戰，提供了克服開發過程中常見障礙的見解。
- 這些化合物為製藥行業提供了顯著的機會，以提供更有效和量身定制的癌症治療，進一步推動市場增長。
- 雜環抗癌藥物的市場範圍廣泛，隨著科學進步揭示新的治療靶點，市場仍在持續擴展。
作者簡介
Dr. Larbi EL Mchichi holds a PhD in Chemistry with a specialization in Theoretical Chemistry from Moulay Ismail University (Faculty of Sciences, Meknes). His doctoral research focused on the anticancer activity of heterocyclic organic molecules, using statistical and quantum methods, including QSAR modeling and molecular docking.
In his research, Dr. EL Mchichi explores innovative computational approaches to the design of novel therapeutic agents, particularly anticancer compounds, utilizing techniques like 3D-QSAR, drug-likeness assessment, ADMET prediction, and molecular docking simulations.
In addition to his research, he is a first-grade certified teacher of physics and chemistry at the secondary education level, where he strives to inspire his students with a passion for science and research.
Dr. EL Mchichi has authored several peer-reviewed publications in international journals, including work on the design of pyrazole derivatives as anticancer agents and the discovery of a new isatin scaffold for BCR-ABL tyrosine kinase inhibitors.
His research aims to contribute to the advancement of cutting-edge cancer therapies through the integration of computational methods and pharmaceutical science.
作者簡介(中文翻譯)
拉比·艾爾·穆奇奇博士擁有摩洛哥穆萊伊斯梅爾大學（梅克內斯科學院）的化學博士學位，專攻理論化學。他的博士研究專注於使用統計和量子方法（包括QSAR建模和分子對接）來研究雜環有機分子的抗癌活性。
在他的研究中，艾爾·穆奇奇博士探索創新的計算方法來設計新型治療劑，特別是抗癌化合物，利用3D-QSAR、藥物相似性評估、ADMET預測和分子對接模擬等技術。
除了研究外，他還是一名中學階段的物理和化學一級認證教師，努力以對科學和研究的熱情來激勵學生。
艾爾·穆奇奇博士在國際期刊上發表了多篇經過同行評審的論文，包括設計作為抗癌劑的吡唑衍生物和發現用於BCR-ABL酪氨酸激酶抑制劑的新型異靛藍骨架的研究。
他的研究旨在通過整合計算方法和藥物科學，為尖端癌症療法的進步做出貢獻。
